Lifesci Capital Reiterates Outperform Rating for Mineralys Therapeutics (NASDAQ:MLYS)

Mineralys Therapeutics (NASDAQ:MLYS)‘s stock had its “outperform” rating reissued by analysts at Lifesci Capital in a note issued to investors on Tuesday, Zacks.com reports. Lifesci Capital also issued estimates for Mineralys Therapeutics’ FY2024 earnings at ($2.04) EPS.

Mineralys Therapeutics Price Performance

MLYS stock opened at $12.78 on Tuesday. Mineralys Therapeutics has a 52-week low of $5.85 and a 52-week high of $17.70. The company has a 50-day moving average of $13.17 and a two-hundred day moving average of $10.10. The stock has a market capitalization of $634.27 million and a price-to-earnings ratio of -6.39.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.24. Equities analysts expect that Mineralys Therapeutics will post -2.64 EPS for the current fiscal year.

Insider Buying and Selling

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was purchased at an average price of $13.50 per share, with a total value of $7,499,992.50. Following the completion of the transaction, the insider now directly owns 5,074,916 shares of the company’s stock, valued at approximately $68,511,366. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Institutional Trading of Mineralys Therapeutics

Several large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in Mineralys Therapeutics by 16.7% during the second quarter. JPMorgan Chase & Co. now owns 10,820 shares of the company’s stock worth $184,000 after buying an additional 1,551 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Mineralys Therapeutics by 8.3% during the third quarter. Federated Hermes Inc. now owns 22,293 shares of the company’s stock valued at $212,000 after purchasing an additional 1,700 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Mineralys Therapeutics by 15.3% during the third quarter. Rhumbline Advisers now owns 17,174 shares of the company’s stock valued at $163,000 after purchasing an additional 2,279 shares during the last quarter. CWM LLC bought a new stake in shares of Mineralys Therapeutics during the third quarter valued at approximately $25,000. Finally, American International Group Inc. grew its stake in shares of Mineralys Therapeutics by 38.7% during the fourth quarter. American International Group Inc. now owns 9,656 shares of the company’s stock valued at $83,000 after purchasing an additional 2,692 shares during the last quarter. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.